IGM Biosciences, Inc. (IGMS) - Dilution Analysis

POS AM filing: This is a post-effective amendment to deregister securities from previous filings S-3 registration statements due to a merger with Concentra Biosciences, LLC.

POS AM filing: This is a post-effective amendment to deregister securities due to a merger with Concentra Biosciences, LLC, terminating all offerings of securities pursuant to the Registration Statements.

POS AM filing: This is a Post-Effective Amendment filing to deregister securities due to a merger with Concentra Biosciences, LLC, terminating all offerings under the Registration Statements.

POS AM filing: This is a post-effective amendment to deregister unsold securities from previous filings due to the completion of a merger agreement.

POS AM filing: This post-effective amendment removes from registration all securities registered under the Registration Statements (Nos. 333-249863, 333-258644, 333-258641, 333-268136 and 333-275519) that remain unsold as of August 14, 2025, and terminates the effectiveness of the Registration Statements due to the merger with Concentra Biosciences, LLC.

10-Q filing | 36.6M shares outstanding

10-Q filing | 34.7M shares outstanding

10-K filing | 34.4M shares outstanding

10-Q filing | 34.1M shares outstanding

10-Q filing | 33.9M shares outstanding

10-Q filing | 33.6M shares outstanding

10-K filing | 33.3M shares outstanding

S-3 filing: IGM Biosciences, Inc. is filing an S-3 to offer common stock, non-voting common stock, preferred stock, debt securities, depositary shares, subscription rights, and purchase contracts, with an aggregate offering price not to exceed $400,000,000.

10-Q filing | 32.9M shares outstanding

10-Q filing | 32.9M shares outstanding

10-Q filing | 29.5M shares outstanding

10-K filing | 29.5M shares outstanding

S-3 filing: IGM Biosciences, Inc. files an S-3 form for a shelf offering of common stock, non-voting common stock, preferred stock, debt securities, depositary shares and subscription rights, with an aggregate offering price not to exceed $400,000,000.

10-Q filing | 29.1M shares outstanding

10-Q filing | 29.0M shares outstanding

10-Q filing | 27.4M shares outstanding

8-K filing: IGM Biosciences, Inc. completed a public offering of 8,695,653 shares of its non-voting common stock at a price to the public of $23.00 per share, with the underwriters exercising their option to purchase an additional 1,304,347 shares of common stock at $21.85 per share, resulting in gross proceeds of approximately $230.0 million. ($230.0M proceeds)

10-K filing | 26.1M shares outstanding

10-Q filing | 26.0M shares outstanding

S-3 filing: IGM Biosciences, Inc. may offer common stock, non-voting common stock, preferred stock, depositary shares, warrants, debt securities, subscription rights and units up to an aggregate amount of $400,000,000.

S-3 filing: This S-3 filing registers 24,747,658 shares of common stock for sale by selling stockholders of IGM Biosciences, Inc. The company will not receive any proceeds from the sale.

10-Q filing | 25.6M shares outstanding

10-Q filing | 25.6M shares outstanding

10-K filing | 25.6M shares outstanding

S-3 filing: IGM Biosciences, Inc. may offer, from time to time, common stock, preferred stock, depositary shares, warrants, debt securities, subscription rights or units up to an aggregate amount of $400,000,000.

10-Q filing | 24.3M shares outstanding

10-Q filing | 24.2M shares outstanding

10-Q filing | 24.2M shares outstanding

10-K filing | 24.1M shares outstanding